Clareo Health | A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed advanced solid tumor for which no curative or standard therapies exist
Karnofsky performance status of ≥ 60
Life expectancy of \>12 weeks
Adequate hematologic and organ function
Negative serum pregnancy test (women only)
Two methods of birth control for female participants of child-bearing potential or male participants with their female partners of child-bearing potential
You may not be if
Prior chemotherapy or investigational treatment within 4 weeks of study drug administration
Prior biological or immunological treatment within 6 weeks of study drug administration
Concurrent therapy for of cancer
Major surgery within four weeks or minor surgery within two weeks of study drug administration
History of diabetes or current treatment for diabetes
New York Heart Association ≥ Grade 2 congestive heart failure
History of myocardial infarction, unstable angina, transient ischemic attack or stroke within the previous 6 months prior to study entry
History of other invasive malignancy within 5 years (exceptions are cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that are surgically cured)
Significant active infection
Known brain metastases
Pregnancy or lactation or plans to become pregnant while on study
